Combination therapy with amlodipine or trichlormetiazide added irbesartan in hypertensive patients with diabetes

Combination therapy with amlodipine or trichlormetiazide added irbesartan in hypertensive patients with diabetes - Combination therapy with amlodipine or trichlormetiazide added irbesartan in hypertensive patients with diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007297

Enrollment

120

Registered

2012-02-15

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with diabetes

Interventions

combination with trichlormethiazide added irbesartan combination with amlogdipine added irbesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)20 years old 2)Hypertensive patients with diabetes 3)patient whose blood pressure did not reach the lebels reccomended by Hypertension Guidelines 2009 of Japanese Association,even when administered standard dose of irbesartan.

Exclusion criteria

Exclusion criteria: 1)Hypersensitivity to or contraindication of irbesartan,trichlometiazide and amlodipine 2)within 3 months after onset of acute myocardial infarction 3)Symptomatic (NYHA3or4)congestive heart failure 4)Severe renal dysfunction or severe liver dysfunction 5)Pregnancy or its possibility 6) subjects whose doctor in charge do not agree to join the trial patients judged as inappropriate for the sutudy

Design outcomes

Primary

Measure	Time frame
1.blood pressure 2.Renal function(urinaru albumin eGFR)	—

Secondary

Measure	Time frame
1.to evaluate the therapy if it could better responded to the patients with low or high sodium 2.PAC	—

Countries

Japan

Contacts

Public ContactTakashi Yoneda

Kanazawa University Hospital Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026